Novome-Bio-Logo-RGB

Engineering
Living Medicines
for Chronic Diseases

We don’t discover drugs.

We build them.

The future of medicine is cellular. We engineer cell therapies to outsmart chronic diseases. Therapies that are precise, extensible, and act symbiotically with the patient to achieve long-term health. Beyond smart, our therapies are alive.

We don’t discover drugs.

We build them.

The future of medicine is cellular. We engineer cell therapies to outsmart chronic diseases. Therapies that are precise, extensible, and act symbiotically with the patient to achieve long-term health. Beyond smart, our therapies are alive.

GEMMs: Genetically Engineered Microbial Medicines

The first platform for colonizing the gut with engineered microbes.

The microbes in our gut are living pharmacies, producing and consuming many molecules that impact our health. Novome’s unique synthetic biology tools allow us to plug into this ecosystem and deliver precise activities to treat chronic diseases.

Founded on pioneering technology from Stanford University, our platform enables controllable engraftment of GEMMs in the gut for sustained and truly effective therapies.

Engineered

We engineer bacterial strains to express therapeutic genes at clinically meaningful levels

Colonizing

Our microbes colonize the gut for an extended period of time at a predictable abundance

Controllable

Colonization is maintained and tuned with a daily dose of a prebiotic polysaccharide

Engineered

We engineer bacterial strains to express therapeutic genes at clinically meaningful levels

Colonizing

Our microbes colonize the gut for an extended period of time at a predictable abundance

Controllable

Colonization is maintained and tuned with a daily dose of a prebiotic polysaccharide

Our Advantages

The Ideal Modality for Treating Chronic Diseases

Chronic diseases are complicated. Treatment shouldn’t be.

Novome’s platform addresses areas where current therapeutic approaches struggle, enabling multiple targets to be engaged in a dynamic fashion with simple, non-invasive dosing. Manufacturing an intelligent, universal therapeutic is possible with GEMMs.

Well-defined Mechanisms of Action

Our therapies utilize well-studied, highly-abundant gut microbes, programmed with targeted activities.

Tunable Treatment

Treatment is tailored to specific conditions by tuning expression of each therapeutic activity.

Convenient Delivery

GEMMs are designed to controllably expand in the gut of any patient, enabling small, oral doses of a universal strain.

Safe and Non-invasive

The gut is our body’s natural interface with foreign cells, making it the ideal site to deploy long-term cell therapies.

Press

Pipeline

The path to living medicines.

Our pipeline targets a variety of indications based on clinical need and regulatory endpoints. Our first programs focus on diseases with clear, mechanistic etiology that are readily addressed with defined activities.

Our lead indication, hyperoxaluria, is a leading cause of kidney stones and affects hundreds of thousands of people in the US alone. We’ve developed a therapeutic strain that breaks down oxalate before it can be absorbed.

IndicationsPhase
DiscoveryProof of ConceptLead OptimizationPhase 1
Hyperoxaluria
Lead Optimization
Irritable Bowel Syndrome
Proof of Concept
Additional Indications
Discovery
Hyperoxaluria
Irritable Bowel Syndrome
Additional Indications

Our People

Blake Wise
CEO
Will DeLoache
Will DeLoache, PhD

CSO, Co-Founder
Wes Whitaker
Weston Whitaker, PhD
VP of Research, Co-Founder
Liz Shepard
Liz Shepherd, PhD

Co-Founder
Zachary Russ
Zachary Russ, PhD
Co-Founder
Domenique Banta
Domenique Banta
Masters Student/RA
Adam Chazin-Gray
Adam Chazin-Gray
Research Associate
Clare Gill
Clare Gill
Lab Manager/RA
Quiana Knight
Quiana Knight
Research Associate
Shu Kurosaki
Shu Kurosaki
Controller
Lauren Popov, PhD
Scientist
Harneet Rishi
Harneet Rishi, PhD
Scientist
Lucas Waldburger
Lucas Waldburger
Research Associate
Lane Weaver
Lane Weaver, PhD
Head of Business Development
Justin Sonnenburg
Justin Sonnenburg, PhD
Co-Founder, Scientific Advisory Board
Kiersten Stead
Board of Directors
Dan Janney
Board of Directors
Andy Schwab
Andy Schwab
Board of Directors
MIra Chaurushiya
Mira Chaurushiya, PhD
Board Observer
John Dueber
John Dueber, PhD
Scientific Advisory Board
Alan Pao
Alan Pao, MD
Scientific Advisory Board
Dave Cook
Dave Cook, PhD
Non-clinical Advisor
Mason Freeman
Mason Freeman, MD
Clinical Advisor
Risa Stack
Risa Stack, PhD
Strategic Advisor
Neil Schauer
Neil Schauer, PhD
CMC Advisor

Investors

Careers

At Novome, we are looking for curious and creative people to join our team. Those willing to question the status quo to drive the future of precision therapeutics.

We are located on the Verily campus in South San Francisco.

Open Positions
 

Careers

At Novome, we are looking for curious and creative people to join our team. Those willing to question the status quo to drive the future of precision therapeutics.

We are located on the Verily campus in South San Francisco.

Open Positions